| Rheumatoid Arthritis

Humira vs Ruxience

Side-by-side clinical, coverage, and cost comparison for rheumatoid arthritis.

Deep comparison between: Humira vs Ruxience with Prescriber.AI

AI compares prescribing info and payer-specific access barriers across 1,200+ formularies. Here's a preview of what prescribers are already asking.

Safety signalsRuxience has a higher rate of injection site reactions vs Humira based on FDA-approved prescribing information

Coverage gaps3 major payers require step therapy for Ruxience but not Humira, including UnitedHealthcare

Category

Humira

Ruxience

At A Glance

RouteSC injection

FrequencyEvery other week

ClassTNF-alpha antagonist

RouteIV infusion

ClassCD20-directed cytolytic antibody

Indications

Rheumatoid Arthritis
Juvenile arthritis
Arthritis, Psoriatic
Ankylosing spondylitis
Crohn Disease
Ulcerative Colitis
Chronic small plaque psoriasis
Hidradenitis Suppurativa
Uveitis

Lymphoma, Non-Hodgkin
Chronic Lymphocytic Leukemia
Rheumatoid Arthritis
Granulomatosis with polyangiitis
Microscopic Polyarteritis
Pemphigus Vulgaris

Dosing

Rheumatoid Arthritis, Arthritis, Psoriatic, Ankylosing spondylitis 40 mg SC every other week; some RA patients not receiving MTX may increase to 40 mg every week or 80 mg every other week.

Juvenile arthritis, Uveitis (pediatric) Weight-based SC dosing every other week: 10 mg (10 kg to <15 kg), 20 mg (15 kg to <30 kg), or 40 mg (>=30 kg) for patients 2 years of age and older.

Crohn Disease 160 mg SC on Day 1 (in one day or split over two consecutive days), 80 mg on Day 15, then 40 mg every other week starting Day 29.

Ulcerative Colitis 160 mg SC on Day 1 (in one day or split over two consecutive days), 80 mg on Day 15, then 40 mg every other week starting Day 29; discontinue if no clinical remission by 8 weeks (Day 57).

Chronic small plaque psoriasis, Uveitis 80 mg SC initial dose, then 40 mg every other week starting 1 week after the initial dose.

Hidradenitis Suppurativa 160 mg SC on Day 1 (in one day or split over two consecutive days), 80 mg on Day 15, then 40 mg every week or 80 mg every other week starting Day 29.

Lymphoma, Non-Hodgkin 375 mg/m2 IV; once weekly for 4 or 8 doses (relapsed/refractory), on Day 1 of each chemotherapy cycle for up to 8 doses (previously untreated follicular or DLBCL), or every 8 weeks for 12 doses as single-agent maintenance.

Chronic Lymphocytic Leukemia 375 mg/m2 IV on Day 1 of Cycle 1, then 500 mg/m2 IV on Day 1 of Cycles 2-6 in combination with fludarabine and cyclophosphamide, every 28 days.

Rheumatoid Arthritis Two 1,000 mg IV infusions separated by 2 weeks (one course) every 24 weeks or based on clinical evaluation, but not sooner than every 16 weeks, in combination with methotrexate.

Granulomatosis with polyangiitis, Microscopic Polyarteritis Induction: 375 mg/m2 IV once weekly for 4 weeks; follow-up: two 500 mg IV infusions separated by 2 weeks, then 500 mg IV every 6 months based on clinical evaluation, in combination with glucocorticoids.

Pemphigus Vulgaris Two 1,000 mg IV infusions separated by 2 weeks plus tapering glucocorticoids; maintenance: 500 mg IV at Month 12 and every 6 months thereafter; relapse: 1,000 mg IV, no sooner than 16 weeks after the previous infusion.

Contraindications

—

Drug Interactions

1222View drug interactions

537View drug interactions

Adverse Reactions

Most common (>=5%) Injection site reactions, upper respiratory infection, headache, rash, accidental injury, sinusitis, urinary tract infection, nausea, hyperlipidemia, abdominal pain, flu syndrome, hypercholesterolemia, back pain.

Serious Serious infections (pneumonia, septic arthritis, prosthetic and post-surgical infections, erysipelas, cellulitis, diverticulitis, pyelonephritis), tuberculosis, opportunistic infections, malignancies, severe hepatic reactions including acute liver failure, new-onset lupus-like syndrome.

Postmarketing Diverticulitis, large bowel perforations, pancreatitis, liver failure, autoimmune hepatitis, sarcoidosis, Merkel Cell Carcinoma, demyelinating disorders, cerebrovascular accident, interstitial lung disease, pulmonary embolism, Stevens Johnson Syndrome, cutaneous vasculitis, erythema multiforme, new or worsening psoriasis, alopecia, lichenoid skin reaction, systemic vasculitis, deep vein thrombosis.

Most common (>=25%) Infusion-related reactions, fever, lymphopenia, chills, infection, asthenia (NHL); infusion-related reactions, neutropenia (CLL).

Serious Infusion-related reactions, severe mucocutaneous reactions, hepatitis B reactivation with fulminant hepatitis, progressive multifocal leukoencephalopathy, tumor lysis syndrome, infections, cardiovascular adverse reactions, renal toxicity, bowel obstruction and perforation.

Postmarketing Prolonged pancytopenia, marrow hypoplasia, late-onset neutropenia, fatal cardiac failure, uveitis, optic neuritis, systemic vasculitis, pleuritis, lupus-like syndrome, serum sickness, polyarticular arthritis, vasculitis with rash, viral infections including PML, Kaposi's sarcoma progression, severe mucocutaneous reactions, pyoderma gangrenosum, bowel obstruction and perforation, fatal bronchiolitis obliterans, fatal interstitial lung disease, PRES/RPLS.

Pharmacology

Adalimumab is a recombinant human IgG1 monoclonal antibody that binds specifically to TNF-alpha, blocking its interaction with the p55 and p75 cell surface TNF receptors and inhibiting TNF-mediated inflammatory and immune responses, including modulation of adhesion molecules responsible for leukocyte migration.

Rituximab-pvvr is a chimeric monoclonal antibody that targets the CD20 antigen on pre-B and mature B-lymphocytes, mediating B-cell lysis through complement dependent cytotoxicity (CDC) and antibody dependent cell mediated cytotoxicity (ADCC).

View Full FDA Information

View full FDA information

Enter your patient's insuranceCheck specific coverage details for your patient.

Most Common Insurance

Anthem BCBS

Humira